|
|
|
| Relationship between Her-2, Topo-Ⅱα and clinicopathological parameters in patients with breast cancer and their significance in evaluating the efficacy of neoadjuvant chemotherapy |
| LIU Yan1 LIU Shuzhen2 MA Hao3 XU Xiuping1 MENG Wenjuan1 GAO Yuan1 YU Guohua2 |
1.Clinical Medical School of Weifang Medical College, Shandong Province, Weifang 261053, China;
2.Department of Medical Oncology, Weifang People′s Hospital, Shandong Province, Weifang 261041, China;
3.Department of Pathology, Weifang People′s Hospital, Shandong Province, Weifang 261041, China |
|
|
|
Abstract Objective To investigate the relationship between Her-2 and clinicopathological parameters and the relationship between Topo-Ⅱα and clinicopathological parameters, and analyze the clinical significance of Her-2 and Topo-Ⅱα expression in neoadjuvant chemotherapy based on anthracycline. Methods From January 2016 to October 2017, 54 patients in Weifang People's Hospital diagnosis of breast invasive cancer after underwent tumor puncture and their paraffin-embedded tissues were selected. The expression levels of ER, PR, KI-67, and Her-2 of all patients were detected. The expression of Topo-Ⅱα of all patients were detected by immunohistochemistry, the expression of Her-2 and Topo-Ⅱα in patients with different therapeutic effects was observed. Results Among the 54 patients, 48 patients had lymph node metastasis. The positive rate of Her-2 was 88.9%, and the positive rate of Topo-Ⅱα was 87.0%. Her-2 expression was not associated with age, size, location, axillary lymph node metastasis (P > 0.05), and was related to stage and genotype (r = -0.3, 0.3, P < 0.05). The expression of Topo-Ⅱα was not related to age, size, location, axillary lymph node metastasis, stage, or subtype (P > 0.05). The expression of Topo-Ⅱα was positively correlated with Her-2 (r = 0.7, P < 0.05). The ORR of Her-2 negative patients was 50.0%; the ORR of Her-2 positive patients was 75.0%, the difference was statistically significant (P < 0.05). The ORR of Topo-Ⅱα positive patients was 78.7%, and the ORR of Topo-Ⅱα negative patients was 28.6%. The difference was statistically significant (P < 0.05). The ORR of patients with Topo-Ⅱα and Her-2 positive was 80.4%, and the ORR of patients with Topo-Ⅱα and Her-2 negative was 20.0%. The difference was statistically significant (P < 0.05). Conclusion Immunohistochemical examination of Her-2 and Topo-Ⅱα has important guiding significance for the treatment of breast cancer. Topo-Ⅱα positive expression can effectively improve the anthracycline-assisted treatment. Topo-Ⅱα and Her-2 may have sensitizing effect in neoadjuvant chemotherapy.
|
|
|
|
|
|
[1] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[2] Jemal A，Bray F，Center MM，et al. Global cancer statistics [J]. CA Cancer J Clin，2011，61（2）：69-90.
[3] Gonzalez-Angulo AM，Morales-Vasquez F. Overview of resistance to systemic therapy in patients with breast cancer [J]. Adv Exp Med Biol，2007，608：1-22.
[4] 石海洲，王笃杰，丁文贤，等.新辅助化疗对晚期乳腺癌患者血浆 microRNA 及肿瘤相关指标的影响研究[J].中国实用医刊，2015，4（22）：4-6.
[5] CSCO乳腺癌诊疗指南（2017.V1）重磅颁布[J].中国全科医学，2017，20（15）：1844.
[6] 乳腺癌HER2检测指南（2014版）编写组.乳腺癌HER2 检测指南（2014版）[J].中华病理学杂志，2014，43（4）：262-267.
[7] Schwartz LH，Bogaerts J，Ford R，et al. Evaluation of lymph nodes with RECIST 11 [J]. Eur J Cancer，2009，45（2）：261-267.
[8] Burden DA，Osheroff N. Mechanism of action of eukaryotic topoisomerase Ⅱ and drugs targeted to the enzyme [J]. Biochim Biophys Acta，1998，1400（1-3）：139-154.
[9] Jain CK，Roychoudhury S. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase Ⅱ inhibitor [J]. Biochim Biophys Acta，2015， 1853（5）：1195-1204.
[10] Lin HF，Huang HL，Liao JF，et al. Dicentrine Analogue-Induced G2/M Arrest and Apoptosis through Inhibition of Topoisomerase Ⅱ Activity in Human Cancer Cells [J]. Planta Med，2015，81（10）：830-837.
[11] Villman K，St?覽hl E，Liljegren G，et al. Topoisomerase Ⅱ-alpha expression in different cell cycle phases in fresh human breast carcinomas [J]. Mod Pathol，2002，15（5）：486-491.
[12] 石毅然，曲建军，李湘洲，等.MUC1与HER2基因在乳腺癌中的表达及其与临床病理学指标的相关性研究[J].中国肿瘤临床，2007，34（11）：621-624.
[13] 邓巍，谢洪，孙晓菊，等.口腔鳞状细胞癌C-erbB-2蛋白表达基因扩增及其临床意义[J].中国实用口腔科杂志，2014，7（5）：290-293.
[14] 帅萍.乳腺癌组织中HER2和Topo Ⅱα的表达及其临床意义[J].中南大学学报：医学版，2016，41（11）：1143-1147.
[15] 贾新建.Her2和TopoⅡ在乳腺癌组织中的表达水平与新辅助化疗疗效的关系研究[J].河北医学，2016，22（8）：1287-1290.
[16] 蒋奕，叶洪涛，姬逸男，等.乳腺癌组织TOP2A和HER2/neu扩增与临床病理因素相关性研究[J].中华肿瘤防治杂志，2017，24（1）：30-33.
[17] 许洁，陈洁，张科平，等.非特殊性浸润性乳腺癌TOP2A基因状态与分级、HER-2和Ki-67的相关性[J].临床与实验病理学杂志，2015，31（5）：576-578.
[18] 李蕊，于国华，张居民，等.TopoⅡ，Her-2对晚期乳腺癌紫杉类药物化疗敏感性的预测分析[J].潍坊医学院学报，2013，35（5）：379-383，401
[19] 孙冰，宋三泰，江泽飞，等.乳腺癌新辅助化疗病理完全缓解的影响因素分析[J].中华肿瘤杂志，2013，35（1）：38-42.
[20] Rastogi P，Anderson SJ，Bear HD，et al. Preoperative che-motherapy：updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. Clin Oncol，2008，（26）：778-785.
[21] 康虹.乳腺癌新辅助化疗疗效评价及pCR影响因素分析[D].宁夏：宁夏医科大学，2016.
[22] DiLeo A，Desmedt C，Bartlett JM，et al. HER-2 and TOPO-2A aspredictive markers for anthracycline containing chemotherapy regimens as adjuvant treat-ment of breast cancer：a meta-anal-ysis of indivi-dual patient data [J]. Lancet Oncol，2011，12（12）：1134-1142.
[23] 何敏，李卉，王珏.乳腺癌患者HER2、TOP2A基因表达与蒽环类药物疗效的关系[J].内蒙古医学杂志，2016， 48（2）：146-149.
[24] Yao L，Liu Y，Li Z，et al. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer [J]. Ann Oncol，2011，22（6）：1326-1331.
[25] Taucher S，Rudas M，Mader RM，et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer [J]. Breast Cancer Res Treat，2003，82（3）：207-213.
[26] 杨会杰，魏民，李鸿超，等.乳腺癌患者HER2表达水平的不同检测方法比较及临床意义[J].癌症进展，2017， 15（10）：1186-1189.
[27] 桑蝶，王佳玉，徐兵河，等.Ki67指数预测Luminal型HER2-乳腺癌新辅助化疗疗效的临床价值[J].癌症进展，2016，14（3）：251-252，255. |
|
|
|
